Chronic myeloid leukemia following the treatment of rectal adenocarcinoma

Abstract

Solid tumors may occur in 3% of the patients with chronic myeloid leukemia (CML). Philadelphia (Ph)-positive CML was diagnosed in a 66-year-old man upon a white blood cell count of 58.1 x 10(9)/L. He had no symptoms and physical findings 3 years after treatment for rectal adenocarcinoma. Imatinib mesylate 400 mg/day was started and white blood cell count was lowered to 5.7 x 10(9)/L in 1 month. The patient had received several chemotherapeutic agents such as 5-fluorouracil, irinotecan, raltitrexed, capecitabine, and oxaliplatin. In the literature, there are two reports on CML after the treatment of colorectal carcinoma. The possibility of a relationship between oxaliplatin and/or irinotecan and CML may not be fully excluded. In conclusion, hematological disorders such as CML may emerge in colorectal carcinoma and whole blood counts should be carefully checked. The possibility of a relationship between CML and the chemotherapeutic agents in colorectal carcinoma should be further evaluated.

Chronic Myeloid Leukemia in Patient with Local Recurrence Colon Cancer: A Case Report

“…Our case was treated with bevacizumab because KRAS mutation. A study (Kadikoylu et al, 2008), reported that 5-flurouracil, oxaliplatin, irinotecan, each of them can be carcinogenic and also in other case report (Vakili-Sadeghi and Omranpour, 2013) the case received these drugs during colon cancer that developed CML. In this study, the patient for colon cancer was treated with capecitabine, oxaliplatin and irinotecan.…”

“…Although CML accounts for a small percentage of secondary leukemia, reports on treatment-related CML are increasing and several cases of CML in patients treated for thyroid cancers, esophageal, gastric, lung, cervical, malignant fibrous histiocytoma and breast cancers have been reported (Vakili-Sadeghi and Omranpour, 2013). Cancer treatment modalities, including radiotherapy and chemotherapy, could themselves increase the risk of developing secondary malignancies (Kadikoylu et al, 2008). NRAS/BRAF mutation probably is effective in treatment of colorectal cancer patients with KRAS wild-type and in patients with KRAS wild-type should be specified NRAS/BRAF testing to determine which patients will benefit from anti-EGFR therapy (Payandeh et al, 2015a).…”

“…Also Chronic Myeloid Leukemia (CML) is a chronic disease that about 50% of patients are more than 60 years old and about 50% of patients are asymptomatic (Payandeh et al, 2015b). The CML is characterized by anemia, extreme blood granulocytosis and granulocytic immaturity, basophilia, often thrombocytosis and splenomegaly (Kadikoylu et al, 2008). There has been a lot of discussion on the likelihood of development of a non-hematological second malignancy in patients with CML Int.…”

Two Secondary Acute Lymphoblastic Leukemia Cases Developed After Cancer Treatment: Case Report

“…10 Çoğunlukla tedavi ilişkili miyeloid neoplaziler gözlenmesine rağmen ALL vakaları da gözlenmektedir. 8,11 Ishizawa ve ark., tedavi ilişkili lösemilerde %12'sinin ALL vakaları olduğunu rapor etmişlerdir.…”

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer

“…These clinical manifestations have featured both types of t-MN. The clinical characteristics of 8 patients who developed TRL after treatment with OXP are summarized in table 1 [7, 8, 9, 10, 11, 12, 13]. There were 5 male and 3 female patients with a mean age of 64 years (range, 25–79).…”